The FDA asked an 18-member panel to recommend guidelines for monitoring more than a half-million U.S. patients with metal hip...
The MHRA in the UK has issued guidance on hip implants (large head implants) requiring blood tests to check for...
OrbusNeich announced that the company's Genous Stent is associated with a significantly lower rate of binary restenosis compared to bare...
This guideline covers assessing and managing heavy menstrual bleeding (menorrhagia).
A soothing and protective cream for the skin.
Patients have encountered Stryker hip replacement problems and developed symptoms similar to those seen in metal-on-metal hip replacement devices. Stryker...
W. L. Gore & Associates, better known as just Gore, won FDA approval for its GORE TIGRIS vascular stent. The...
Myovant Sciences and Pfizer Inc. announced that the FDA has approved Myfembree (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg), the first once-daily treatment for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women, with a treatment duration of up to 24 months.
Biosimilars can be effective in reducing the burden of immune-mediated inflammatory diseases (IMIDs).